Methods of treatment and maintenance therapy for bladder cancer using gemcitabine
Provided are methods of treating urothelial carcinomas of the lower tract comprising administering comprising administering gemcitabine continuously and locally to the bladder of an individual in an induction therapy and/or maintenance therapy.
1. A method of providing maintenance therapy for an individual,
wherein the maintenance therapy follows at least one previous therapy, wherein the maintenance therapy comprises
administering gemcitabine continuously to the individual two or more times during two or more delivery periods
wherein the gemcitabine is delivered locally to the bladder of the individual,
wherein each delivery period is at least one week,
wherein there is a rest period between each delivery period of at least one month, and
wherein the individual has muscle invasive bladder cancer.
2. The method of claim 1 , wherein the gemcitabine is delivered into the bladder by an intravesicular device.
3. The method of claim 2 , wherein the intravesicular device contains about 225 mg gemcitabine.
4. The method of claim 1 , wherein the delivery periods are each 3 weeks.
5. The method of claim 1 , wherein the rest period is about 3 months.
6. The method of claim 1 , wherein the gemcitabine is delivered at a dose from about 1 mg/day to about 300 mg/day during delivery periods.
7. The method of claim 1 , wherein the concentration of gemcitabine in the urine is from about 1 μg/mL to about 10 μg/mL during the first and second delivery period.
8. The method of claim 7 , wherein the concentration of gemcitabine in the urine is about 10 μg/mL during the delivery periods.
9. The method of claim 1 , wherein the individual is ineligible for or has refused cisplatin-based chemotherapy.
10. The method of claim 1 , wherein the individual is unfit for, ineligible for, or has refused a radical cystectomy.
11. The method of claim 1 , wherein the rest period between the delivery periods is about 3 months.
12. The method of claim 1 , comprising 4 delivery periods, wherein the rest period between each delivery period is about 3 months.
13. The method of claim 1 , wherein the rest period between each delivery period is about 3 months, and wherein the gemcitabine is delivered about every 3 months for the lifetime of the individual.
14. A method of treating muscle invasive bladder cancer in an individual comprising
a) administering to the individual continuously an effective amount of gemcitabine during an induction phase; and
b) administering to the individual continuously an effective amount of gemcitabine during a maintenance phase, wherein the gemcitabine is delivered locally to the bladder of the individual, wherein the induction phase and maintenance phases are separated by a rest period, and wherein the induction phase is about 12 weeks.
15. A method of bladder preservation in an individual comprising
a) administering to the individual continuously an effective amount of gemcitabine during an induction phase; and
b) administering to the individual continuously an effective amount of gemcitabine during a maintenance phase, wherein the gemcitabine is delivered locally to the bladder of the individual, wherein the induction phase and maintenance phases are separated by a rest period, wherein the induction phase is about 12 weeks, and wherein the individual has muscle invasive bladder cancer.
16. The method of claim 14 , wherein the gemcitabine is delivered by an intravesicular device.
17. The method of claim 16 , wherein the intravesicular device contains about 225 mg gemcitabine.
18. The method of claim 14 , wherein the rest period between the induction phase and the maintenance phase is about 3 months.
19. The method of claim 14 , wherein the maintenance phase comprises two or more gemcitabine delivery periods.
20. The method of claim 19 , wherein the maintenance phase gemcitabine delivery periods are each separated by a rest period of about 3 months.
21. The method of claim 14 , wherein the maintenance phase gemcitabine delivery periods are each 3 weeks.
22. The method of claim 19 , wherein the gemcitabine is delivered at a dose from about 1 mg/day to about 300 mg/day during the induction phase or the maintenance phase delivery periods.
23. The method of claim 19 , wherein the concentration of gemcitabine in the urine is from about 1 μg/mL to about 10 μg/mL during the induction phase or the maintenance phase delivery periods.
24. The method of claim 14 , wherein the individual is ineligible for or has refused cisplatin-based chemotherapy.
25. The method of claim 14 , wherein the individual is unfit for, ineligible for or has refused a radical cystectomy.